Apogee Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Apogee Therapeutics, Inc. Common Stock (APGE) has an Asset Resilience Ratio of 47.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Apogee Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Check Apogee Therapeutics, Inc. Common Stock (APGE) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Apogee Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Apogee Therapeutics, Inc. Common Stock worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $608.09 Million | 47.01% |
| Total Liquid Assets | $608.09 Million | 47.01% |
Asset Resilience Insights
- Very High Liquidity: Apogee Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 47.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Apogee Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Apogee Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Apogee Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.88% | $598.64 Million | $937.13 Million | +13.63pp |
| 2024-12-31 | 50.25% | $378.86 Million | $753.95 Million | -18.79pp |
| 2023-12-31 | 69.04% | $277.14 Million | $401.40 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $152.06 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more